<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659606</url>
  </required_header>
  <id_info>
    <org_study_id>12-950</org_study_id>
    <secondary_id>IRB-P00003466</secondary_id>
    <nct_id>NCT01659606</nct_id>
  </id_info>
  <brief_title>Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita</brief_title>
  <official_title>Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyskeratosis congenita is a disease that affects numerous parts of the body, most typically&#xD;
      causing failure of the blood system. Lung disease, liver disease and cancer are other&#xD;
      frequent causes of illness and death. Bone marrow transplantation (BMT) can cure the blood&#xD;
      system but can make the lung and liver disease and risk of cancer worse, because of DNA&#xD;
      damaging agents such as alkylators and radiation that are typically used in the procedure.&#xD;
      Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA&#xD;
      damaging agents in patients with DC, and still have a successful BMT. In this protocol we&#xD;
      will test whether a regimen that avoids DNA alkylators and radiation can permit successful&#xD;
      BMT without compromising survival in patients with DC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents&#xD;
      with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC&#xD;
      is part of a spectrum of telomere biology disorders, which include some forms of inherited&#xD;
      idiopathic aplastic anemia, myelodysplastic syndrome, and pulmonary fibrosis and the&#xD;
      congenital diseases Hoyeraal-Hreidarsson syndrome and Revesz syndrome. Progressive bone&#xD;
      marrow failure (BMF) occurs in more than 80% of patients under 30 years of age and is the&#xD;
      primary cause of morbidity and mortality, followed by pulmonary failure and malignancies.&#xD;
      Allogeneic hematopoietic cell transplantation (HCT) is curative for the hematological&#xD;
      defects, but several studies have demonstrated poor outcomes in DC patients due to increased&#xD;
      early and late complications. A predisposition to pulmonary failure, vascular disease and&#xD;
      secondary malignancies may contribute to the high incidence of fatal complications following&#xD;
      HCT in DC patients, and provides an impetus to reduce exposure to chemotherapy and&#xD;
      radiotherapy in preparative regimens. Recent studies suggest that fludarabine-based&#xD;
      conditioning regimens provide stable engraftment and may avoid the toxicities seen after HCT&#xD;
      for DC, but studies to date are limited to case reports, retrospective studies and a single&#xD;
      prospective trial. In this study, we propose to prospectively evaluate the efficacy of a&#xD;
      fludarabine- and antibody-based conditioning regimen in HCT for DC patients, with the goals&#xD;
      of maintaining donor hematopoiesis and transfusion independence while decreasing early and&#xD;
      late complications of HCT for DC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2034</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary engraftment</measure>
    <time_frame>Up to day +100 post-BMT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival to day+100 post-BMT</measure>
    <time_frame>Up to day+100 post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reactivation and infection</measure>
    <time_frame>Up to day +100 post-BMT</time_frame>
    <description>Number of participants with DNA virus (cytomegalovirus, Epstein Barr virus, or adenovirus) reactivation/infection detected by PCR screening will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events as assessed by CTCAE version 4.0</measure>
    <time_frame>Up to 1 year post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary graft failure</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic graft-versus-host disease (GVHD)</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment monitoring (chimerism)</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution as assessed by quantitation of lymphocyte subsets</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
    <description>Number of participants with quantitative defects in lymphocyte subset numbers following BMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulmonary function as assessed by pulmonary function testing</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary malignancies</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
    <description>Number of patients with malignancies following BMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term survival</measure>
    <time_frame>Up to 15 years post-BMT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dyskeratosis Congenita</condition>
  <condition>Hoyeraal Hreidarsson Syndrome</condition>
  <condition>Revesz Syndrome</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alemtuzumab/fludarabine conditioning; cyclosporins/mycophenolate mofetil GVHD prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Conditioning: alemtuzumab 0.2 mg/kg/dose IV x 5 doses</description>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>Campath-1H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>fludarabine 30 mg/m2/dose IV x 6 doses</description>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>cyclosporine A</other_name>
    <other_name>Neoral</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>alemtuzumab/fludarabine conditioning</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bone marrow hypocellular for age&#xD;
&#xD;
          -  Moderate or severe aplastic anemia defined by one of the following: peripheral blood&#xD;
             neutrophils &lt; 0.5 x 10^9/L; platelets &lt; 30 x 10^9/L or platelet transfusion&#xD;
             dependence; reticulocytes &lt; 50 x 10^9/L in anemic patients or red cell transfusion&#xD;
             dependence&#xD;
&#xD;
          -  Diagnosis of dyskeratosis congenita based on clinical triad of abnormalities of skin&#xD;
             pigmentation, nail dystrophy, oral leukoplakia; OR one of clinical triad and presence&#xD;
             of two or more associated features; OR a pathogenic mutation in DKC1,TERC, TERT,&#xD;
             NOP10, NHP2, TCAB1, TINF2, CTC1, PARN, RTEL1, or ACD as reported by a CLIA-approved&#xD;
             laboratory; OR age-adjusted mean telomere length &lt; 1%ile in peripheral blood&#xD;
             lymphocytes as reported by a CLIA-approved laboratory; OR Hoyeraal-Hreidarsson&#xD;
             syndrome; OR Revesz syndrome&#xD;
&#xD;
          -  Availability of a related or unrelated donor with a 7/8 or 8/8 match for HLA-A, B, C,&#xD;
             and DRB1.&#xD;
&#xD;
          -  Patient and/or legal guardian must be able to sign informed consent.&#xD;
&#xD;
          -  Donor must provide a marrow allograft.&#xD;
&#xD;
          -  Diagnosis of Fanconi anemia must be excluded by mitomycin C or diepoxybutane&#xD;
             chromosomal breakage testing on peripheral blood at a CLIA-approved laboratory (not&#xD;
             required for patients with a genetic mutation consistent with DC)&#xD;
&#xD;
          -  Adequate renal function with glomerular filtration rate equal to or greater than 30&#xD;
             ml/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow&#xD;
             examination.&#xD;
&#xD;
          -  Karnofsky/Lansky performance status &lt; 40.&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or fungal infections.&#xD;
&#xD;
          -  Positive test for the human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab,&#xD;
             cyclosporine, or mycophenolate mofetil.&#xD;
&#xD;
          -  Positive patient anti-donor HLA antibody, which is deemed clinically significant.&#xD;
&#xD;
          -  Prior allogeneic marrow or stem cell transplantation.&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suneet Agarwal, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suneet Agarwal, MD, PHD</last_name>
    <phone>617-919-7579</phone>
    <email>suneet.agarwal@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Arieli</last_name>
      <phone>323-361-5744</phone>
      <email>karieli@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pulsipher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Gruntorad, MS, CCRP</last_name>
      <phone>773-702-6554</phone>
      <email>sgruntorad@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>James LaBelle, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Perry, RN</last_name>
      <phone>617-724-2638</phone>
      <email>lindsey.perry@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Yi-Bin Chen, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital (pediatric patients)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <phone>617-919-7579</phone>
      <email>suneet.agarwal@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Lehmann, MD</last_name>
      <email>leslie_lehmann@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leslie Lehmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (adult patients)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <email>suneet.agarwal@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Antin, MD</last_name>
      <email>Joseph_Antin@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suneet Agarwal, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Antin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Hull</last_name>
      <phone>507-422-4820</phone>
      <email>hull.jennifer2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>William J. Hogan, M.B.,B.Ch.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hall, MD</last_name>
      <phone>816-302-6808</phone>
      <email>emhall@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred P Gillio, MD</last_name>
      <phone>551-996-5600</phone>
      <email>Alfred.Gillio@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Alfred P Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Pediatric BMT</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda S. Brown, RN</last_name>
      <phone>919-668-1100</phone>
      <email>linda.brown@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Vinod K. Prasad, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasiani Myers, MD</last_name>
      <email>Kasiani.Myers@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Kasiani Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barb McGlynn</last_name>
      <phone>215-590-1303</phone>
      <email>MCGLYNN@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Tim Olson, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghadir Sasa, MD</last_name>
      <phone>832-824-4524</phone>
      <email>gssasa@txch.org</email>
    </contact>
    <investigator>
      <last_name>Ghadir Sasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics, American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Weiland</last_name>
      <phone>608-890-8070</phone>
      <email>jlweiland@pediatrics.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peds Hem Onc Main Office</last_name>
      <phone>608-263-6200</phone>
      <email>PedsHemOncResearch@lists.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Inga Hofmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Büchner, MD, PHD</last_name>
      <phone>+47 2307 4560</phone>
      <email>jocbuc@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Jochen Büchner, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Sundin, MD, PHD</last_name>
      <phone>+46 8 585 848 43</phone>
      <email>mikael.c.sundin@sll.se</email>
    </contact>
    <investigator>
      <last_name>Mikael Sundin, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Suneet Agarwal</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>dyskeratosis congenita</keyword>
  <keyword>bone marrow failure</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>reduced intensity conditioning</keyword>
  <keyword>campath</keyword>
  <keyword>fludarabine</keyword>
  <keyword>telomere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

